top of page

Thinking
laterally
about CAR-T

Our mission is to develop next generation CAR-T therapies using the Company’s proprietary Lateral CAR platform to improve treatment outcomes and save the lives of patients with refractory cancers

Latest News

​

ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with Leucid Bio

+ read more

​

imagecells.jpg

Join us at Advanced Therapies 2023 where our CSO, Dr John Maher, will discuss Leucid's exciting pipeline technologies for enhancing CAR T-cell efficacy in solid tumours

14th-15th March 2023

ExCeL, London

Screenshot 2022-10-14 at 12.11.46.png
Lateral CAR T-Cell Platform

Founded to translate 20 years of pioneering CAR-T research led by Dr John Maher at King's College London (King's), Leucid Bio has developed a proprietary portfolio based upon Dr Maher’s novel approach, in which the CAR structure has been redesigned to recapitulate the lateral distribution of signalling domains as observed in natural immune receptors. The technology gives properties to the CAR-Ts that enable them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies; enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.

pCAR + description (1).png
shutterstock_1275172360.jpg
T4 Immunotherapy

Leucid Bio’s T4 Immunotherapy is a pan-ErbB targeted autologous CAR T-cell product for patients with otherwise untreatable head and neck cancer. It is currently in Phase I, with 18 patients treated to date, of whom 10 have achieved disease stabilisation.

Novel Manufacturing Platforms

Leucid Bio has developed an improved, more rapid and scalable manufacturing process that relies on a simple blood draw.

1 (17).2.jpg
5d166a945fd97_edited.jpg

Our Science

Next generation CAR T-cell therapy to revolutionise the technology in which immune cells, called T-cells, are reprogrammed so they can recognise and destroy cancer cells.

Lateral CAR T-Cell Platform

Founded to translate 20 years of pioneering Chimeric Antigen Receptor T-Cell (CAR-T) research led by Dr John Maher at King's College London (KCL), Leucid Bio has developed a proprietary Lateral CAR platform that builds upon Dr Maher’s novel  novel CAR-T model  in which the CAR structure has been redesigned to recapitulate the lateral distribution of signalling domains as observed in natural immune receptors. This technology gives properties to the CAR-T enabling them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies; enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.

CAR T cell.png
5d26f8578751d.png
T2, gd T-cells for off-the-shelf cell therapy

Leucid has developed a patented technique for generating gd T-cells from the peripheral blood of healthy donors, we call T2. T2 cells are a distinct population of gd T-cells and ideally suited for off-the-shelf cellular therapy.

Lead asset - LEU011

LEU011 is a lateral CAR targeting NKG2D ligands.  Currently in pre-clinical development for the treatment of solid tumours and haematological malignancies. The NKG2D receptor is an activating immune receptor that triggers cell death upon recognition of one or more of the eight human NKG2D ligands expressed on transformed, infected or damaged cells.

NKG2D CAR T TX_edited.jpg
Novel Manufacturing Platforms

Leucid Bio has developed an improved, more rapid and scalable manufacturing process that relies on a simple blood draw.

1 (17).2.jpg
Contact us
bottom of page